Category Archives: Regenerative Medicine

VIKEN, Sweden, Aug. 3, 2022 /PRNewswire/ -- A new study with TikoMed's lead drug candidate, ILB, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published in the International Journal of Molecular Sciences today. The data from the rodent model studying severe traumatic brain injury (sTBI), demonstrated that ILB administration 30 minutes after sTBI prevents glutamate excitotoxicity and normalizes levels of amino acids involved in crucial brain metabolic functions.

"The study shows the beneficial effect of ILB on post-impact brain metabolism using a single dose of the drug administered in a window of time corresponding with situations as seen with TBI patients in clinical settings. It is clear that the results of this study appear of great relevance for future applications in the treatment of TBI patients," said Professor Giuseppe Lazzarino", Principal Investigator and Professor at the Department of Biomedical and Biotechnological Sciences, University of Catania.

This study provides evidence that the therapeutic administration of ILB uses a unique mechanism to activate growth factors that protect nerve cells in the brain from damage by significantly improving mitochondrial functions and energy metabolism, as well as decreasing oxidative/nitrosative stress of rats exposed to severe traumatic brain injury.

"TBI is a silent epidemic with limited treatment options currently available, so this research demonstrates the development of a drug candidate activating natural molecules to protect and repair damaged brain tissues. Significantly improved neurocognitive functions, as demonstrated in this study, reinforce the potential of ILB as a completely new therapy for the treatment of sTBI, as well as other neurodegenerative conditions", added Ann Logan, Co-Author and Scientific Director at Axolotl Consulting Ltd-, and Professor of Regenerative Medicine at the University of Warwick.

Traumatic brain injuries result in both short and long-term effects on individuals, their families, and society and the economic costs are enormous. To date, there are no satisfactory pharmacological treatments capable of decreasing mortality/morbidity and improving the recovery of sTBI patients.1,2.

"These results are a significant milestone for TikoMed as they demonstrate ILB's potential as a disease modifying treatment, enabling neurons to regain lost functions even in an acute neurodegenerative disease such as TBI. We remain confident in our ongoing clinical development program with ILB in acute and chronic degenerative neurological diseases and will shortly be presenting additional study results validating ILB's unique effects and mechanism of action," said Anders Kristensson, CEO of TikoMed.

Contact: info@tikomed.com or +46 42 23 84 40

Media:International: Richard Hayhurst, richard@rhapr.eu or +44 7711 821527Nordics: Ola Bjorkman, ola.bjorkman@letemknow.se or +46 70 245 7497

About TBI

Traumatic brain injury (TBI) is one of the most common acute neurodegenerative diseases and represents the leading cause of death for those under 45 years of age in Western countries. Depending on the severity of the symptoms, evaluated by the Glasgow Coma Scale, TBI is classified as mild (mTBI) and moderate or severe (sTBI). Severe TBI is characterized by a high mortality rate and those who survive often suffer from profound disabilities with permanent impairment of cognitive, physical and psychosocial functions, associated with a diminished or altered state of consciousness and inability to be independent, work correctly and maintain social relationships.1

About TikoMed AB

TikoMed is committed to improve human life by exploring and harnessing the medical potential of the body's ability to self-repair and regenerate. With an adaptive, multi-modal mechanism of action, TikoMed's drug platform rebalances the body's inflammatory, immune and fibrotic responses to acute and chronic inflammation in order to enhance self-repair and regeneration. Currently applied as a therapy in neurodegeneration and an enabling technology for advanced therapies, the initial development programs include Amyothrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation. Broader use of the drug platform will be considered for a wider range of diseases using a creative business and financing model. TikoMed's highly scalable proprietary technology aims to provide safe, qualitative and affordable medicine to as many patients as possible across the globe. TikoMed is privately-owned and based in Viken, Sweden. To learn more, visit http://www.tikomed.com

The International Journal of Molecular Sciences is a peer-reviewed, fully open access international journal. For full study details on "ILB, a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury", please access the publication here: https://www.mdpi.com/1422-0067/23/15/8460

References

1. Abdelmalik, P.A.; Draghic, N.; Ling, G.S.F. Management of moderate and severe traumatic brain injury. Transfusion 2019, 59(S2):1529-1538.

2. Scerrati, A.; De Rosa, S.; Mongardi, L.; Cavallo, M.A.; Trapella, G.; De Bonis, P. Standard of care, controversies, and innovations in the medical treatment of severe traumatic brain injury. J Neurosurg Sci 2018, 62, 574-583.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/tikomed/r/tikomed-s-ilb--activates-the-body-s-natural-repair-signals-to-restore-glutamate-homeostasis--amino-a,c3609428

Read the original post:
TikoMed's ILB activates the body's natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a...

Image source: Getty Images

The AVITA Medical Inc(ASX: AVH) share price has shot well into the green in lunchtime trade on Wednesday.

At the time of writing, the companys shares are 19.88% higher at $2.05 apiece on no news.

In broader market moves, the S&P/ASX 200 Health Care Index (ASX: XHJ) is 0.35% lower so far today.

Lets check what may be going on.

Its been a quiet few months from the regenerative medicine company, although not so much on the charts.

Avita shares have eroded more than 40% this year to date, after gliding from a high of $5.61 on 2 September 2021.

They found a bottom almost a year later at $1.32 on 17 June.

However, the healthcare share has caught a bid since then and now trades more than 42% higher on the month, and up 27% in the past five days of trade.

While theres been no news from Avitas end, two things stand out. First, the company is set to report earnings next week on 11 August.

Second is that healthcare shares have been strengthening ever since we rolled into the new financial year.

As seen on the chart below, both the healthcare benchmark index and the Avita share price bounced from lows in late June and have curled up since.

In the absence of any company-specific updates, it stands to reason the share might be attracting buyers on the back of this sector strength.

With Avita due to post earnings next week, investors may also be expecting a strong report from the company.

Either way, it looks a little early to tell if the Avita share price has completely turned the corner. In the last 12 months, it is down 61% and has some catching up to do.

Follow this link:
Why is the Avita Medical share price tracking 20% higher today? - The Motley Fool Australia

Wilmington, Delaware, United States, Transparency Market Research Inc.: According to the report, the global urinary catheters market was valued at US$ 3.5 Bn in 2020 and is projected to expand at a CAGR of 4.5% from 2021 to 2028. Urinary catheters are used to drain and/or collect urine from the bladder. Urinary catheters are available in different shapes, sizes, materials (latex, silicon, Teflon, etc.) and types (Foley, coude tip, straight, etc.).

Urinary catheters have been categorized into three major segments: Foley (indwelling) catheters, intermittent (temporary) catheters, and male external (condom) catheters. Urinary catheterization is often recommended when an individual is suffering from disorders such as urinary incontinence, urinary retention disorder, post prostrate or genital surgery or multiple sclerosis, or neurological disorders such as Parkinsons disease or dementia.

People suffering from such disorders often show symptoms such as lack of efficient control over urination and a few face difficulties in urine discharge. Hence, urinary catheters help these patients with proper urine drainage and/or collection, thereby maintaining sanitary conditions and helping patients recover faster.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3936

Presently, physicians prefer intermittent catheters due to several applications and advantages. Urinary catheters are used in hospitals, specialty clinics, ambulatory surgery centers, etc. These devices are designed with several properties, such as the degree of hydrophilic coating, softness, track ability, and stability.

COVID-19 Impact on Urinary Catheters Market

COVID-19 has hampered businesses and economic activities globally, and is expected to have a short-term negative effect on the urinary catheters market. Urinary catheters are used for surgical applications and be affected to some extent due to the temporary postponement of various elective surgeries, as government authorities seek to ensure the availability of resources for COVID-19 patients. Various governments have provided guidelines on elective surgeries in an effort to minimize the strain on the healthcare system, decrease disease transmission, and conserve personal protective equipment (PPE).

Ask for References - https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=3936

As on March 18, 2020, the U.S. CMS announced that all elective surgeries, as well as non-essential medical, surgical, and dental procedures, would be delayed. Other areas that are negatively affected include the supply of products meant for hospitals (including ICUs, neurological care centers, emergency rooms, and trauma patients), owing to lockdowns and mobility restrictions in various countries across the globe. However, businesses are likely to revive and resume normalcy once restrictions on elective surgeries and movement are lifted.

Increase in Number of Urinary Bladder Disorders

Rise in the number of diseases related to bladder dysfunction such as urinary incontinence and neurovascular diseases, technological innovations, surge in the geriatric population, favorable insurance & reimbursement policies, and increase in per capita healthcare expenditure are projected to drive the global urinary catheters market.

Increase in demand for urinary catheters and rise in the number of surgical procedures are other drivers of the global urinary catheters market. Increase in the incidence of chronic disorders has resulted in the rise in demand for urinary catheters globally. According to a report published by the WHO, around 200 million people suffer from one or the other urological problems, which essentially require urinary catheterization.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3936

Intermittent Catheters Segment to Dominate Global Market

In terms of product type, the global urinary catheters market has been classified into intermittent catheters, Foley Catheters, and male external catheters. The intermittent catheters segment held the largest share of the global urinary catheters market in 2020. The segment's dominance can be attributed to short-term or temporary catheterization. This feature has helped reduce the ever-increasing incidence of CAUTIs, which is one of the major forms of healthcare-associated infections (HCAIs) in developed countries.

Indwelling or Foley catheters have been primarily associated with CAUTIs due to the catheterization of hospitalized patients for considerably longer duration. Other factors fueling the expansion of the segment are driving the demand and acceptability among healthcare professionals as well as patients and fewer side effects associated with these urinary catheters.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=3936

North America to Dominate Global Market

In terms of region, the global urinary catheters market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global urinary catheters market in 2020, followed by Europe.

North America is projected to lead the global urinary catheters market during the forecast period, followed by Europe. The U.S. is anticipated to dominate the market in North America largely due to larger population and well-established healthcare infrastructure. Well-established pharmaceutical and biotechnology industry, increase in research activity, rise in prevalence of neurological disorders are factors driving the market in the region.

Competition Landscape

The global urinary catheters market is fragmented in terms of number of players. Key players in the global market include Teleflex Incorporated, Hollister Incorporated, ConvaTec, Inc., Medtronic plc, Cook Medical, Boston Scientific Corporation, Coloplast, C. R. Bard, Inc., B. Braun Melsungen AG, TE Connectivity Corporation, and other prominent players.

More Trending Reports by Transparency Market Research

Medical Nonwoven Disposables Market: The market for medical nonwoven disposables is expected to reach a value of ~US$ 20 Bn by the end of 2028.

Radiodermatitis Market: The global radiodermatitis market was valued at US$ 334.2 Mn in 2018 and is projected to expand at a CAGR of 3.3% from 2019 to 2027.

Peptide Therapeutics Market: The global peptide therapeutics market was valued at US$ 25.0 Bn in 2018 and is anticipated to expand at a CAGR of 7.9% from 2019 to 2027.

Menopausal Hot Flashes Treatment Market: The menopausal hot flashes treatment market is expected to grow at a CAGR of 6% during the forecast period.

Diabetic Foot Ulcers Treatment Market: The global diabetic foot ulcers treatment market is projected to reach a market value of ~US$ 9.6 Bn by the end of 2027.

Recto-vaginal Fistula Treatment Market: The global recto-vaginal fistula treatment market is expected to cross the value of US$ 1 Bn by the end of 2031.

Regenerative Medicine Market: The global regenerative medicine market is expected to reach the value of US$ 12.9 Bn by the end of 2028.

Surgical Navigation Systems Market: The worth of the global surgical navigation systems market stood at US$ 0.8 Bn in 2021. The global market is likely to expand at a CAGR of 6.3% during the forecast period, from 2022 to 2031.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Continued here:
Urinary Catheters Market Insights by Leading Companies and Emerging Growth till 2028 - BioSpace

The Healthcare Technology Report is pleased to announce The Top 100 Healthcare Technology Companies of 2022. The awardees on this years list represent the absolute best in the healthcare technology space. From companies like Novartis with more than 100,000 team members around the globe, to numerous smaller startups with just a few dozen employees in a single office, these companies are changing the face of the industry. They are leveraging their considerable talent to find innovative solutions to the most pressing issues in healthcare, and they are saving countless lives and extending healthspans in the process.

Some of this years awardees include Hologic, whose growth across breast and skeletal health, diagnostic solutions, and GYN surgical solutions is driven by the clinically proven ability of its products to detect, diagnose, and treat illnesses and other health conditions earlier and better; Integra LifeSciences, which offers a broad portfolio of products and solutions for dural access and repair, cerebral spinal fluid management, and neuro-critical care; and Axtria, whose best-in-class cloud-based analytics platforms have leveraged AI and machine learning to help life sciences operators make the most of their data for the benefit of their clients.

The top 100 companies this year represent a range of specialties, from genomics to pharmaceuticals, lab testing, therapeutics, data analysis, and much more. What they have in common is the impact they are having on patients lives, whether through direct treatment or by providing advanced, game-changing products and services to treatment providers. They are driving the industry forward and creating an environment in which better care for all is possible. Please join us in celebrating The Top 100 Healthcare Technology Companies of 2022.

1. NovartisCategory: Biotech

As one of the largest pharmaceutical companies in the world, Novartis has continued to break new ground in delivering innovative medical solutions to almost 1 billion people around the world. It employs approximately 125,000 individuals in its international offices and production facilities, most notably from its headquarters in Basel, Switzerland and Cambridge, Massachusetts.

Novartis was born out of the 1996 merger of Ciba-Geigy and Sandoz, and the new company quickly grew to push the boundaries of achievement in cancer-fighting drugs and other essential pharmaceutical products. The company has attracted a great deal of praise from industry and civil organizations for the benefits of its generic drugs, which have been praised by the Access to Medicine Index for widening access to medicine among underserved populations. Amid a difficult period for multinationals, Novartis has shown impressive growth in its major brands, and its continued developments in multiple sclerosis treatments have been met with international acclaim.

2. StrykerCategory: Medical Devices

Michigan-based medtech company Stryker is recognized as an industry leader in the field, designing and manufacturing devices used in hospitals and care facilities in more than 100 countries. Strykers main offerings are divided into the segments Orthopedics, MedSurg, and Neurotechnology and Spine, the latter of which has seen groundbreaking advances in recent years. Boasting more than 46,000 employees around the world, the company has posted a remarkable four decades of consistent growth over its lifetime, reporting over $17 billion in sales in 2021.

Founded as the Orthopedic Frame Company by Kalamazoo orthopedist Dr. Homer Stryker in 1941, the company has made a name for itself in its production of medical devices that quickly become indispensable for modern health care. Stryker has frequently been hailed as a forward-thinking workplace, having been named to Fortunes list of the worlds best workplaces five years in a row. Most recently, it has made waves with the launch of its new Global Technology Center, a unique 150,000-square-foot R&D facility in New Delhi designed to supercharge the companys capacity to develop new life-saving innovations.

3. Edwards LifesciencesCategory: Medical Devices

Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, the company collaborates with the worlds leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. As the pioneer of many products considered industry standard, including the transcatheter aortic valve replacement, Edwards products are sold in approximately 100 countries around the world. Founded by engineer Miles Lowell Edwards in 1958, the company has 16,000 employees around the world with manufacturing operations in North America, Europe, Singapore, and the Caribbean.

The Edwards Lifesciences Foundation supported more than 250 global charities in 2021 and continued its work with Every Heartbeat Matters, the Foundations primary philanthropic initiative, to improve the lives of 2.5 million additional underserved structural heart and critical care patients by the end of 2025.

To advance social equity, Edwards established a Social Impact Investment Fund with $100 million to support economic development in predominantly Black and underserved communities in the U.S. When Edwards was established as a separate company from Baxter in 2000, the company was formed around a credo which serves as a reminder to always put patients first, and that as a company Edwards will remain committed to making a positive impact on the quality of life for patients around the world.

4. Centura HealthCategory: Consumer HealthTech

Faith-based health care nonprofit Centura Health is known as a leader in high-quality health care services throughout Colorado and western Kansas. Its network of 17 hospitals and 6,000 physicians are responsible for delivering the best possible medical outcomes to traditionally underserved communities across the region. Centura traces its roots to a dedicated, compassionate order of Catholic sisters in 1882, and has pushed since its founding 25 years ago to deliver on that mission of building healthy people and communities.

As befits an organization that was founded on the value of altruistic service, Centura has developed a reputation as an invaluable supporter of local communities, launching initiatives to promote food security, mental and behavioral health, and rural community care. It has contributed a great deal of resources and attention to supporting community hospitals and rural communities in seven different countries, and recently issued a $5 million health equity and advancement grant to help regional organizations enhance health outcomes across the board.

5. HologicCategory: Medical Devices

Headquartered in Marlborough, Massachusetts, Hologic and its team of more than 6,700 have created an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While Hologic discovers and develops groundbreaking products and services that benefit everyone, they are especially passionate about those that advance womens health and well-being, allowing the company to prosper and grow while empowering women to experience healthier lives.

None of this would be possible without the talent, skills, and aspirations of Hologics employees. Since its founding in 1985, the company has expanded to more than 100 countries and territories and holds more than 3,000 patents. Its employees expertise and dedication to developing and sharing more robust, science-based certainty drives Hologics increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families, and communities.

Hologics growth across breast and skeletal health, diagnostic solutions, and GYN surgical solutions is driven by the exceptional and clinically proven ability of its products to detect, diagnose, and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which the team at Hologic fulfills by always challenging itself to improve health through better technology, education, and market access. The companys goal is to minimize doubt and maximize the confidence its customers and their patients have in their decisions and diagnoses. By focusing on womens health while still delivering health benefits to everyone, Hologic is setting a new standard of excellence that is strengthened by purpose, driven by passion, and brought to life by its promise of more certain early detection and better health outcomes.

6. Access HealthcareCategory: Software & Data

Access Healthcare provides business process outsourcing, applications services, and robotic process automation tools to hospitals, health systems, providers, payers, and related service providers. The company operates from 19 global delivery centers in the U.S., India, and the Philippines. Their 25,000+ staff is committed to bringing revenue cycle excellence to clients by leveraging technology, emerging best practices, and global delivery. Based in Dallas, Texas, the company supports more than 400,000 healthcare providers through 85+ clients, serving 80+ specialties, processing more than $70 billion in accounts receivable annually, and ascribing medical codes to more than 30 million charts annually.

With more than 3,500 virtual bots in operation, Access Healthcare's proprietary robotic process automation platform helps its clients improve efficiency. Access Healthcare is HITRUST, PCI DSS, SOC, ISO 27001, and ISO 9001 certified, providing security, availability, and confidentiality of sensitive health information.

7. CitiusTechCategory: Software & Data

CitiusTech is a partner of choice to the worlds largest healthcare and life sciences organizations to accelerate digital innovation, drive business transformation, and enable industry-wide convergence. With more than 7,000+ healthcare technology professionals, CitiusTech provide strategic consulting, digital engineering, data, analytics & AI, specialized platforms, and end-to-end solutions to more than 130 organizations across the payer, provider, medtech, and life sciences industries.

CitiusTechs cutting-edge technology expertise, deep healthcare domain expertise, and a strong focus on digital transformation enable organizations to deliver better outcomes, accelerate growth, drive efficiencies, and make a meaningful impact to patients, caregivers, and consumers. CitiusTechs deep commitment to world-class quality and unwavering focus on delivery excellence and client satisfaction is evident in their customer satisfaction score of 4.5/5 and a Net Promoter Score (NPS) of over 70.

8. Integra LifeSciencesCategory: MedTech

Integra LifeSciences is a global leader in neurosurgery and regenerative medicine. The company offers a broad portfolio of products and solutions for dural access and repair, cerebral spinal fluid management, and neuro-critical care. Its regenerative tissue technologies include products that address soft tissue, nerve, and tendon repairs and for the treatment of acute and chronic wounds, burns, as well as for plastic and reconstructive surgery.

Founded in 1989 by Richard E. Caruso, the company is headquartered in Princeton, New Jersey. Today, Integra LifeSciences has grown immensely, with more than 3,000 employees worldwide as well as offices, manufacturing, and research facilities in Asia, Australia, Europe, the Middle East, and the Americas. Integra products are ubiquitous in many hospital intensive care units and operating rooms around the world. And some of its leading brands include AmnioExcel, Bactiseal, CerebroFlo, Certas Plus, Codman, CUSA, DuraGen, and DuraSeal. In March, the company launched its newest product: NeuraGen 3D Nerve Guide Matrix , a resorbable implant for the repair of peripheral nerve discontinuities.

9. Jazz PharmaceuticalsCategory: Biotech

Global biotech company Jazz Pharmaceuticals is a tireless pioneer in innovating medical treatments for serious ailments once thought uncurable, such as narcolepsy and schizophrenia. Among the companys best-known productsall of which have provided relief to thousands around the worldare Vyxeos, Xywav, and Jazzs crown jewel, narcolepsy medication Xyrem. For its efforts in the development of these innovative treatments, Jazzs neuroscience and oncology divisions together posted revenues of $814 million in the first quarter of 2022, up more than a third from last year.

First launched in 2003 from Dublin, Ireland, Jazz has grown to expand its corporate presence and manufacturing to multiple sites in Europe and the Americas, and now employs more than 3,100 biotech experts to deliver on its promise of reimagining what is possible in medicine. Following its successful 2021 acquisition of GW Pharmaceuticals, it has pushed to expand its offerings in international markets while continuing to develop daring new treatments for multiple sclerosis and lymphoma.

10. AxtriaCategory: Software & Data

Life sciences technology pioneer Axtria was built to harness the best in cutting-edge data science and cloud technology and use it to improve health outcomes around the world. The company is best known for its best-in-class cloud-based analytics platforms, DataMAx, SalesIQ, InsightsMAx, and CustomerIQ, which have leveraged AI and machine learning to help life sciences operators make the most of their data for the benefit of their clients.

The company was launched by data scientist and onetime Entrepreneur of the Year Jassi Chadha in 2010, and has since expanded to bring new products and services to healthcare providers in 75 countries and counting. In addition to its perpetual placement on Deloittes Fast 500 and Inc. 5000, Axtria has repeatedly been certified a Great Place to Work in both its Indian locations and its U.S. headquarters in Berkeley Heights, New Jersey. Reflective of the high esteem in which the company is held in the life sciences world, Axtria was recently invited to deliver the keynote address on the future of the pharmaceutical world at Reuters Pharma USA 2022 event.

11. Horizon TherapeuticsCategory: Biotech

There may be no grander figure when it comes to the development of medicines for rare and rheumatic diseases than Irish biotech research company Horizon. Leading products such as Krystexxa, Duexis, and Rayos have brought comfort to and improved the lives of millions of individuals around the world who suffer from rare diseases such as gout, thyroid eye disease, and a variety of other inflammatory diseases. Horizons team of more than 2,000 strive to achieve the companys mission from their headquarters in Dublin as well as its U.S. office in Lake Forest, Illinois.

In addition to its already significant work improving the health outcomes of rare disease patients, Horizon supports an impressive array of community outreach initiatives, working to advance STEAM education and environmental sustainability in partner sites around the world. For its labors in these noble fields, the CSR World Leader company was named one of Peoples Companies That Care in 2021, and has received praise from the IBIO Institute and the Communitas Awards.

12. Leica BiosystemsCategory: Biotech

A German cancer diagnostics company that has as its motto Advancing Cancer Diagnostics, Improving Lives, Leica Biosystems provides the world a unique comprehensive diagnostic portfolio built to help identify and beat cancer using the latest technology. Leica is a proud partner of the Mayo Clinics Department of Laboratory Medicine and Pathology, and it works to improve patient outcomes there with the development of new cytogenic imaging software products.

Founded in 1989, Leica has expanded out of its headquarters in Wetzlar, Germany to establish offices across the Americas, Europe, and Asia Pacific. Today, its products are used in more than 100 countries around the globe. Among the companys latest developments in biotechnology are the exploration of innovative applications of artificial intelligence and machine learning in pathology. Further, with the introduction this year of Leicas new advanced, fully automated staining platform BOND-PRIME, it has managed to improve user experience while achieving major revenue growth despite a difficult climate.

13. ModereCategory: Consumer HealthTech

First founded as an all-natural shampoo that delivered on the natural ingredients promise made and broken by so many competitors, Modere has grown to become a household name for science-backed clean label health and beauty products. Its omnichannel consumer products have been featured as standout offerings in personal care and nutrition among its more than 3 million customers, and have been shared on national platforms including Good Morning America, NPR, and Forbes.

Modere has accomplished a great deal since its founding 30 years ago. Led by Chief Executive Officer Asma Ishaq, the company was named the top woman-led company of the year in 2021 by the JPMorgan-backed Women Presidents Organization. Modere was also ranked the #1 fastest growing woman-led company by Forbes, and its state-of-the-art collagen sciences offerings have been hailed by industry voices for raising the bar for consumer applications of the latest health sciences.

14. Penumbra, Inc.Category: Medical Devices

Penumbra, Inc. is a global healthcare company which designs, develops, manufactures, and markets innovative therapies to address complicated medical conditions in a novel way, supporting healthcare providers, hospitals, and clinics in more than 100 countries. Penumbra has redefined care across conditions that impact millions of Americans, including ischemic stroke, peripheral blood clots (clots throughout the body, such as pulmonary embolisms), and aneurysms with first-to-market minimally invasive interventional medical devices that have improved clinical outcomes. Penumbra recently expanded into immersive healthcare using virtual reality to inspire and empower potentially millions of patients to engage and challenge themselves more fully in their physical and cognitive rehabilitation and mental wellness.

As a global market leader that continues to experience double-digit revenue growth year-over-year, Penumbra is committed to advancing innovations that address unmet needs and help as many people as it can with its technologies.

15. PractoCategory: Software & Data

Practo is an Indian healthcare platform renowned for breaking down the barriers between patients and doctors with its signature all-in-one consumer healthcare software. By using Practos video conferencing platform, the company empowers more than one billion Indian people to take charge of their health and make more informed care decisions for their loved ones. Other Practo services include Ray, a practice management software used by thousands of clinics in the country, and Insta, a standout full-stack HIMS solution trusted in more than twenty markets around the world.

Founded in Bangalore and still headquartered there, Practo has a longstanding commitment to privacy and equity that has connected patients and doctors since its establishment in 2008. In remarkable expansions of this mission to traditionally underserved populations, the company added online consultation functionality in 15 vernacular languages at the height of the COVID-19 pandemic, and the launch of a digital veterinary consult option in 2021 has brought Practos game-changing technology into yet another critical market segment.

16. TempusCategory: Biotech

With a stated mission of bringing the frontiers of technology to the world of medicine, Chicago-based biotech research company Tempus is leveraging an incredible data library to apply AI to the establishment of a new era of precision medicine. Tempus offerings empower healthcare partners to more efficiently diagnose patients and model the effectiveness of treatments, and its clinical trial matching capabilities have helped more than 10,000 patients since its founding in 2015.

Tempus is empowered to make use of its greater than 50 petabytes of data thanks to its partnerships with prominent figures across the biotech research world, including 120 biopharma companies and more than half of all academic medical centers in the U.S. As a recognized innovation driver in the industry, the company has announced recent advances in machine learning-based genomic testing, and has presented dozens of papers at this years meetings of the American Association for Cancer Research and the American Society of Clinical Oncology.

17. VerilyCategory: Biotech

Alphabets life science research organization, Verily is dedicated to using the power of data to change how healthcare is managed and delivered. Among the solutions provided by Verily are its evidence generation services, care delivery, and care management, as well as its joint ventures in precision risk management, addiction recovery, and other cutting-edge areas. With new partnerships announced with Lumea and Highmark Health, it is continuing to play an active role in some of the latest developments in health tech.

Verily began as a division of Google X until its transition to an independent subsidiary in 2015. Since then, the company has engaged in a series of expansions that have vastly boosted its profile in the health science research industry, including a remarkable $1 billion fundraise in 2019 and the sale of its robot-assisted surgery venture Verb Surgical. In 2020, the company announced its entry into the insurance market with the launch of a Re Group-backed insurance subsidiary called Coefficient Insurance Company.

18. Carbon HealthCategory: Consumer HealthTech

In a world in which accessing healthcare seems to become more and more difficult and time-consuming for the average consumer, Carbon Health strives to use smart tech to provide a seamless relationship between patient and provider. From its home base in San Francisco, Carbon Healths platform enables individuals across the country to make virtual or in-person appointments with their primary care provider, urgent care provider, or mental or behavioral health specialist. It has also risen to the challenge of the pandemic era by offering expanded services for diabetes care, LGBTQ and womens health, and COVID care programs for employers.

Carbon Health was started in 2015 by immigrant entrepreneurs Eren Bali and Caesar Djavaherian, who saw a gap in the U.S. healthcare system and devised a means to use technology to remove boundaries to care. Having perfected the telemedicine niche at a critical moment of need, the Co-Founders and Chief Executive Officers have steered their company to a $3 billion valuation in just six years, and have continued to change the game in how doctors and patients alike use technology for the care they need.

19. Global Healthcare Exchange (GHX)Category: Software & Data

Founded in 2000 in Louisville, Colorado, GHX is a software-as-a-service company that is reducing the cost of doing business in healthcare by automating supply chain processes and improving visibility into the products used in patient care. The GHX Global Network, the worlds largest community of healthcare trading partners, connects supply chain, finance, and clinical professionals with their suppliers, and the cloud-based technology makes it easier for customers to drive costs out of the healthcare supply chain. Since 2010, GHX has saved the healthcare industry more than $5 billion. Today, the company is expanding its solutions to further enhance data management and allow integration of clinical and business systems.

The focus of GHX is on the healthcare supply chain, through which hospitals and their suppliers buy and deliver the thousands of medical-surgical supplies that clinicians need to effectively care for patients. At the heart of GHX is the GHX Exchange, a platform that connects healthcare providers and suppliers so they can work together electronically. This helps lower costs and simplifies supply chain management by eliminating error-prone, manual order processes. GHX is known for operating the largest healthcare trading network in the U.S., representing more than 80% of licensed beds in the country, with more than 85% of med-surg products flowing through the platform.

20. TELUS HealthCategory: Software & Data

Digital health technology and services provider TELUS Health is the power behind the digital health ecosystem used by 130,000 physicians to treat millions of patients across Canada. From its headquarters in Montreal and its offices throughout the nation, it electronically processes 130 million health insurance claims annually. The company also works to help employers optimize their health insurance packages for their workforces, and its round-the-clock Virtual Care platform directly links people who need healthcare to the appropriate providers.

TELUS Health is a division of Canadian multinational Telus Corporation, a company that has grown over three decades to lead the charge in telecommunications, agriculture, security, and health sciences. TELUS Health has long worked to achieve considerable social good with its corporate activities, recently helping two million Canadians gain access to their own digital health records and opening a mental health clinic in Montreal to better support the community.

21. Tandem Diabetes CareCategory: Medical Devices

Tandem Diabetes Care is a medical device company that has become synonymous with quality, reliable care for diabetes sufferers the world over. Tandem is responsible for the development and production of the t:slim X2 insulin pump with Control-IQ technology, one of the most trusted names in user-friendly digitally enabled insulin pumps for individuals with Type I diabetes.

From its head office in San Diego, Tandem has long characterized itself as a positively different pump manufacturer, working with users to make sure their products are perfectly configured to meet their unique needs. The company has continued to push the envelope when it comes to insulin management, developing new and better device software while leveraging user data to drive new insights into diabetes treatment. Ongoing research has confirmed optimal health outcomes among t:slim X2 users the world over, and with the recent acquisition of insulin set developer Capillary Biomedical, Tandem is preparing to carry their tradition of innovation and service into the future.

22. Cue HealthCategory: Biotech

Out of the many hero companies that arose to help the world meet the challenge of the COVID-19 pandemic, one of the inarguable standouts was California biotech research company Cue Health. In a move that transformed Cue into a household name virtually overnight, the companys interdisciplinary team of 1,200 medical professionals was the first to produce an at-home molecular diagnostic test for COVID, and its approval by the FDA for over-the-counter use brought the benefits of Cues remarkable achievement to millions of beleaguered Americans.

Cue Health has expanded well beyond its 2010 origins, growing to encompass five state-of-the-art buildings at its San Diego headquarters, where its tests and other products are designed, tested, and manufactured. Among the organizations that have come to rely on their partnership with Cue are ConocoPhillips, Johnson & Johnson, and a variety of national sports leagues. The fruits of the companys mammoth achievement included a striking $3 billion valuation last year.

23. CertaraCategory: Software & Data

Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. As a global leader in biosimulation, Certara serves more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Seventeen global regulatory agencies, including the U.S. FDA, Japans Pharmaceuticals and Medical Devices Agency, and Chinas National Medical Products Administration, have adopted Certaras Phoenix PK/PD software and/or Simcyp PBPK Simulator. The Companys COVID-19 Vaccine Model received both an R&D 100 Award and Edison Award in the past year. In October 2021, Certara acquired Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance, and submission readiness.

With its software and global team of nearly 1,200 employees, Certara advances confident decision-making throughout the biopharma R&D lifecycle to help reduce time, lower cost, and improve outcomes for patients. The companys customers who use its software and services have received over 90% of new drug approvals by the FDA since 2014, excluding diagnostics.

24. Thrive GlobalCategory: Enterprise HealthTech

See original here:
The Top 100 Healthcare Technology Companies of 2022 - The Healthcare Technology Report.

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced Precision-T, its pivotal Phase 3 study, is open, enrolling and treating patients at clinical trial sites including Stanford Health Care, City of Hope, Winship Cancer Institute of Emory University, Sarah Cannon Research Institute, Ronald Reagan UCLA Medical Center and Oregon Health & Science University. Precision-T is expected to enroll approximately 174 patients at more than 20 transplant centers across the U.S.

Precision-T (NCT05316701) is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bios lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic hematopoietic stem cell transplant (standard allo-HSCT). Orca Bio received guidance from the Food and Drug Administration on the design of Precision-T, which will evaluate Orca-T in patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and high-risk myelodysplastic syndromes (MDS).

By precision engineering the donor graft, we aim to create a cell therapy that retains the benefits of transplant without serious complications like graft versus host disease and disease relapse, said Robert Negrin, M.D., professor of medicine at the Stanford School of Medicine. This has been demonstrated by the recent results of the Phase 1b/2 single-arm trials with Orca-T, and we are pleased to be evaluating this novel cell therapy in a randomized Phase 3 clinical trial.

The primary endpoint of the Precision-T study is the rate of moderate-to-severe chronic GvHD-free survival. The secondary endpoints are graft-versus-host-disease and relapse-free survival (GRFS), moderate-to-severe chronic GvHD and relapse-free survival. The randomized Phase 3 trial is being conducted concurrently with Orca Bio's ongoing single-arm Phase 1b trial of Orca-T.

The Precision-T study is an important step forward for patients battling deadly blood cancers like AML and ALL, which are often aggressive and for which standard allo-HSCT treatment carries significant risks, said Ivan Dimov, Ph.D., co-founder and chief executive officer of Orca Bio. We are pleased to collaborate with these clinical trial centers and the broader blood cancer community to advance this study with the ultimate goal of delivering a safe and effective therapy to the patients who need it.

Orca-T is a first-in-class high-precision cell therapy that combines purified cells from a matched donor. It is designed to replace a patient's diseased blood and immune system with a healthy one while lowering the risk of developing GvHD and other life-threatening transplant-related side effects. Almost 200 patients have been treated to date with Orca-T in single-arm trials with extremely encouraging results, which were recently presented at the European Hematology Association (EHA) 2022 Congress, the 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings and the American Society of Hematology (ASH) Annual Meeting.

More information about the Precision-T study can be found at http://www.precisiontstudy.com or http://www.clinicaltrials.gov.

About Orca-T

Orca-T is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and is being studied to treat multiple hematologic malignancies.

About Orca Bio

Orca Bio is a late-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than standard allogeneic stem cell transplants, like graft versus host disease and other debilitating transplant-related toxicities. At Orca Bio, we hope to not only replace patients' blood and immune systems with healthy ones, but restore their quality of life. For more information, visit http://www.orcabio.com and follow Orca Bio on Twitter: @orcabio.

Link:
Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S. - Business Wire

Westford, USA, July 26, 2022 (GLOBE NEWSWIRE) -- The cell therapy market is set to grow at an exponential CAGR and will shape patient care in many sectors, and its growth may be reduced only by the inability to control costs. In the last few years, the market has gained an immense popularity for cell therapy across numerous for applications such as cosmetics and transplant. In line with this, the global cell therapy market witnessed a considerable rise in the number of clinical trials undertaken globally. As per SkyQuest analysis, during 2007-2016, more than 251 clinical trials were registered. Wherein, the year 2007, registered the only 3 trials and it went to increase to 116 in 2016. In addition, over 73% of these clinical trials were found to be distributed under non-commercial applications and 26.40 were meant for commercial purpose.

Cell therapy is a rapidly growing field with great potential for treating many diseases including cancer, diabetes, and neurodegenerative diseases. Apart from this, this treatment option has the potential to restore health and improve the quality of life for patients.

In the report published by SkyQuest on Cell Therapy Market, we examine the future of the cell therapy market and related trends innovations that are supporting its growth.

Get sample copy of this report:

https://skyquestt.com/sample-request/cell-therapy-market

Cell Therapy is Ray of Hope for Cancer Patients

Cell therapy is providing hope and healing to cancer patients. This innovative form of treatment is based on reprogramming the cells in the body to fight tumors. Researchers are constantly discovering new ways to target and treat cancer with cell therapy, and it is expected to play an important role in the future of cancer care.

While cell therapy is still relatively new, it has already shown great promise in the treatment of cancer.

Some of the most well-known cell therapies include cancer immunotherapy and adoptive T-cell therapy. Cancer immunotherapy uses the patient's own immune system to fight their cancer. adoptive T-cell therapy works by using T-cells from a donor to help fight the cancer.

The report has explored several active players in the market and how they are performing. One provider that is doing well in the cell therapy industry is OncoCyte Corporation. The company has developed several new therapies that are effective in treating various forms of cancer. OncoCyte currently offers treatments for cervical, lung, and pancreatic cancer. These treatments are reasonably priced, making them a valuable option for patients seeking treatment for their cancer.

Stem Cells is Becoming More Common as a Therapeutic Option

As per SkyQuest Technology, global stem cell therapy market is estimated to grow from $6.87 billion in 2016 to $15.63 billion by 2025. This growth is being driven by the increasing prevalence of disease, rising demand for regenerative medicine, and growing investment in the development of novel cell therapies.

Stem cells are becoming more common as a therapeutic option because they have the ability to become any type of cell in the body. This means that they can be used to treat a wide variety of diseases and injuries. For example, stem cells have been used to successfully treat leukemia and lymphoma. They are also being studied for their potential to treat other types of cancer, Alzheimer's disease, Parkinson's disease, spinal cord injuries, and diabetes.

One of the main drivers of the cell therapy market is the increasing prevalence of diseases such as cancer and neurodegenerative diseases. Cancer is currently the leading cause of death worldwide and killing over 10 million people around the globe every year, and is expected to account for more than half of all deaths by 2030. Cell therapy products that are approved for use in cancer treatment include treatments for leukemia, lung cancer, breast cancer, and several others.

Neurodegenerative diseases are also on the rise, as they are responsible for a large number of disabilities and deaths. Every year, it affects around 2% of the global populated aged 65 and above. Cell therapy products that are approved for use in neurodegenerative disease treatment include treatments for Alzheimers disease, Parkinsons disease, and multiple sclerosis.

Additionally, cell therapy products that are used to regenerate tissue are also driving growth in cell therapy market. These products are not as mature as some of the others in the market, but have exhibited steady growth, and have a chance to further expand. The functionality of cell therapy products extends beyond improving the usability of existing treatment options for cancer, neurodegenerative disease, and other disorders. Employing more effective therapies can offer substantial benefits to those who receive them by reducing pain and improving quality of life.

Despite the promising potential of stem cell therapy, there are still many challenges that need to be addressed before it can become a mainstream treatment option. One of the main challenges is developing an efficient and safe method for delivering stem cells to the target site in the body.

SkyQuest has identified opportunities in stem cell therapy market and how it competing with other available treatment options. The report provider in-depth market analysis, potential opportunities, revenue pockets, company profiles, market dynamics, and current trends.

Browse summary of the report and Complete Table of Contents (ToC):

https://skyquestt.com/report/cell-therapy-market

Regenerative Medicine to Top the Cell Therapy Market

The field of regenerative medicine is one of the most promising and rapidly growing areas in the biomedical sciences. Regenerative medicine focuses on the replacement, repair or regeneration of cells, tissues or organs to restore function in patients with conditions such as heart disease, diabetes and Alzheimers disease. Global regenerative cell therapy market is poised to attain a value of $6.9 billion by 2025.

In recent years, cell therapy market has gained immense popularity and emerged as a leading approach in regenerative medicine for treating a wide range of diseases and injuries, including heart disease, stroke, diabetes, Parkinsons disease and spinal cord injury. As per latest study by SkyQuest, most of the companies offering regenerative cell therapy are located in North America. To be precise, North America is housing around 50% of the global companies active in regenerative cell therapy market. On the other hand, Asia Pacific (27.20%) and Europe (19.30%) are holding second and third largest market share in terms of presence of companies.

The regenerative cell therapy market is expanding at a rapid pace, with investors realizing the potential for this field. In 2021, as per SkyQuest analysis, the market attracted an investment of over $23 billion across gene & gene modified cell therapy, cell therapy, and tissue engineering. However, cell therapy remained the major interest of investors as the segment attracted an investment of more than $12 billion, which is followed by gene and gene modified therapy in 2021. Other major companies include Osiris Therapeutics Inc., and Kite Pharma Ltd. The cell therapy witnessed a significant surge in the investment since 2016, which witnessed an investment of over 1.8 billion, but it went on to grow to $12 billion in 2021. This indicates the how cell therapy market is expanding as more area of application are being explored.

The potential benefits of regenerative cell therapy are vast. The therapies can help treat conditions such as cancer, ALS, diabetes, and heart disease. They can also restore damaged tissues and organs. In addition to treating human patients, Regenerative Medicine Labs is also working on treatments for animals.

Investors are bullish on the potential of this field, with several firms announcing large rounds of funding in recent months. This investment will help drive the development of these therapies further and provide relief to patients worldwide.

SkyQuest has published a new report on cell therapy market that primarily focuses on how the demand for regenerative and stem cell therapy is growing. It dives deep into understanding potential investment pockets, market regulation, analysis of historical investment by sub-segments, opportunities, and market dynamics.

3D Printing is Gaining All the Attention for Custom-Made Implants and Scaffolds for Tissue Regeneration

This little-known technology is capable of engineering 3D scaffolds to allow stem and progenitor cells to proliferate. This has the potential of opening up new possibilities in regenerative cell therapy market such as it can improve the quality of implants and scaffolds. Implant materials are often degraded over time and may need to be replaced. However, with a 3D printer you can create implants using customized templates that are specific to the individual patients needs. This means that implants created using a 3D printer can be more durable and longer lasting than those made using traditional methods.

One of the biggest challenges in regenerative cell therapy market is a lack of viable cells that can be used to repair damaged tissue. Wherein, 3D Printed scaffolds could play a role in solving this problem. A 3D printed scaffold is a type of therapeutic device that is used to promote tissue growth. The scaffold is made from layers of biological materials that have been bonded together using a printing process.

The application of 3D printing to tissue regeneration has many benefits. The first advantage is the flexibility of the scaffold. This allows it to conform to the contours of the tissue that it is replacing. Another major benefit of 3D printed scaffolds is their ability to generate multiple copies of the scaffold. This allows for more rapid healing and more accurate reconstruction of the damaged tissue.

Despite these advantages, there are some potential problems with using 3D printed scaffolds in regenerative cell therapy market. One issue is that they can be difficult to print correctly. This can lead to defects in the scaffold that may interfere with its function.

Overall, 3D printed scaffolds have many potential benefits for regenerative medicine. However, there are still some limitations to be addressed before they can be widely adopted by researchers. SkyQuest technology has covered over 100 clinical trials and their potential application in cell therapy market. This would help the companies in understanding current growth opportunities and development in the market.

Speak to Analyst for your custom requirements:

https://skyquestt.com/speak-with-analyst/cell-therapy-market

Increasing Interest in using Natural or off-the-Shelf Cells for Cell Therapy Rather than Genetically Modified

The use of natural or off-the-shelf cells for cell therapy is an area of increasing interest. The main advantage of using these cells is that they are not genetically modified, which avoids the potential risks associated with genetic modification. Additionally, off-the-shelf cells are readily available and do not require the time and expense of creating a custom cell line for each patient.

There are several types of off-the-shelf cells that have been investigated in the cell therapy market, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs). MSCs can be easily isolated from adult tissue and expanded in culture, making them a readily available source of therapeutic cells. iPSCs can be generated from a patients own skin or blood Cells, meaning they would be immune-compatible with the recipient and would not require immune suppression. ESCs are derived from early-stage embryos and have the ability to differentiate into any cell type in the body; however, their use is limited by ethical concerns.

Prominent Players in Cell Therapy Market

Related Reports in SkyQuests Library:

Global Stem Cell Market

Global Flow Cytometry Market

Global Biomaterials Market

Global Bioinformatics Market

Global Synthetic Biology Market

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:sales@skyquestt.com

LinkedInFacebookTwitter

Continue reading here:
Cell Therapy Market to Generate $35.95 billion, Regenerative Therapy and 3D Printing to Remain in Limelight - GlobeNewswire

The International Society for Stem Cell Application (ISSCA) is hosting the most anticipated regenerative medicine event of he year Regenerative Medicine World Congress 2022. The congress will take place at the Radisson Blu Hotel Istanbul Sisli, Turkey, on September 23. 24. and 25.

The congress features theoretical lectures on the first two days. Physicians and scientists from around the world will present evidence-based research; demonstrate updates on technologies. products, and equipment; share their extensive experience in clinical applications of regenerative medicine and cellular therapies. 30 presentations focusing on stem cell research and regenerative medicine will be given by clinicians and researchers in different specialties. Featured topics include:

Mesenchymal stem cells (MSC).- Exosomes.- Plastic and reconstructive surgery.- Clinical trials.- Nerve injury treatment.- Applications in ophthalmology and cardiology.- Immunotherapy.

The congress will be the ultimate gathering and a showcase of the most cutting-edge research in regenerative medicine. Congress participants will be able to network with like-minded medical professionals from different parts of the world and become part of a growing community leading the future of medicine.

With theAll-Access package, congress participants will have access to thehands-on practice certification portionon the third day. The live practical portion has only 20 limited seats available.

ISSCA-certified instructors, Dr. Maritza Novas (Director of Research and Development at Global Stem Cells Group. USA) and Dr. Melihcan Sezgic (Plastic. Reconstructive and Aesthetic Surgeon. Regenerative Medicine Specialist. Turkey), will lead one-on-one training sessions at the ReGen iC Clinic. This is a great opportunity to gain intensive hands-on experience in the aesthetic and clinical applications of stem cell therapy. The following training modules are included:

Cellular Products

1. Mononuclear layer umbilical cord blood

2. Exosomes: Characterization, examination of growth factors and cytokines

3. Amniotic fluid and its action as a natural anti-inflammatory

Production, Manufacturing, and Quality Control

1. Eligibility and selection of donors

2. Collection and management of samples

3. Processing and laboratory standards

4. Testing and validation of quality control

1. Clinical framework for therapeutic applications

2. Protocol details and supporting scientific literature

3. Product storage and preparation

4. Selection of patients

5. Results and expectations of patients

Application of the Protocol in Live Patients

1. Demonstration of product preparation and injection

About ISSCA:

The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research, and publications.

The Regenerative Medicine World Congress 2022 will be one of the most celebrated events of the year. where we share the ISSCA values in Integrity, Interdisciplinary, and Innovation. The ISSCA invites physicians and healthcare professionals devoted to regenerative medicine to expand their network, access world-class speakers, and update themselves with the latest technologies, products, and equipment.

For more information. please fill out the form tocontact us.

Media ContactCompany Name: ISSCAContact Person: Benito NovasEmail: Send EmailPhone: +1 (305) 560-5337Address:Datran Center 9100 S Dadeland Boulevard, Suite 1500 City: MiamiState: Fl. 33156Country: United StatesWebsite: https://www.issca.us/

See the original post:
ISSCA Announces the Program Agenda of Regenerative Medicine World Congress 2022 - Digital Journal

New Jersey, United States This Regenerative Medicine Market research works as the best evaluation tool to track the progress of the industry and keep an eye on the competitors growth strategies. It further helps to keep you ahead of your business competitors. This report depicts a few potential problems and gives solutions to them by doing comprehensive research on the market scenario. Valuable information is provided here about a particular market segment according to product type, application, region type, and end user. By referring to this comprehensive Regenerative Medicine market analysis report, it becomes possible for organizations to monitor the efficiency of sales, determine the quality of services offered by competitors, estimate the competition level in the market and understand the communication channels followed by competitors in the market.

This Regenerative Medicine Market research report covers career outlooks, regional marketplaces, and an overview of the expectations of a number of end-use sectors. With the help of relevant market data, key organizations are able to obtain a competitive benefit over the competitors in the market and attain the best results for business growth. Furthermore, this Regenerative Medicine market analysis report emphasizes doing a comparison between several various geographical markets in key regions such as North America, Europe, Middle East, Africa, Latin America, and Asia Pacific. It aims at covering complex structures to classifications to an easy-to-follow overview of different business sectors.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=7157

Key Players Mentioned in the Regenerative Medicine Market Research Report:

Organogenesis Inc., Osiris Therapeutics Vericel Corporation, Stryker Corporation and NuVasive, Inc.

A massive amount of information presented in this Regenerative Medicine Market report helps business players to make beneficial decisions. Some of the major key aspects covered in this market analysis are key performance indicators, customer acquisition, and manufacturers list. Performance results of the marketing plan are also covered in this market analysis report. This market study report enables to bring the improvements required in the business. It further talks about how COVID-19 caused huge trauma in several major sectors. Key marketing channels, market growth opportunities, core marketing strategy, and current scope of the business are some of the major factors discussed in this report. It further briefs on the current position of the market. It depicts the effect of metrics on market trends, revenue, and leads.

Regenerative MedicineMarket Segmentation:

Regenerative Medicine Market, By Product

Cell-Based Products Acellular Products

Regenerative Medicine Market, By Therapy

Tissue Engineering Immunotherapy Gene Therapy Cell Therapy Others

Regenerative Medicine Market, By Application

Central Nervous System Diseases Oncology Diabetes Orthopedic & Musculoskeletal Disorders Dermatology Cardiology Others

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Regenerative Medicine market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Regenerative Medicine market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Regenerative Medicine market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Regenerative Medicine market by application, it gives a study on the consumption in the Regenerative Medicine market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Regenerative Medicine market are profiled in this section. The analysts have provided information about their recent developments in the Regenerative Medicine market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Regenerative Medicine market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Regenerative Medicine market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Regenerative Medicine market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Follow this link:
Regenerative Medicine Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee - This Is Ardee

Wilmington, Delaware, United States, Transparency Market Research Inc.: Gelatin, a protein product derived from collagen, plays an important role in joint health and brain function. It also improves appearance of hair and skin. It is formed by partial hydrolysis of collagen.

It is used as an excipient in the pharmaceutical industry. Other applications areas of gelatin include hemostatic applications for bleeding control, drug delivery, and regenerative applications.

Read Report Overview - https://www.transparencymarketresearch.com/low-endotoxin-gelatin-market.html

Endotoxins are immunogenic molecules that are found in outer membrane of gram-negative bacteria. They are heat resistant and initiate immune response when exposed to immune system. This results in tissue inflammation, thereby increasing sensitivity to allergens.

The effect of endotoxin is mediated by the inflammasome and a TLR receptor cytokines

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76802

Key Drivers & Restraints of Global Low Endotoxin Gelatin Market

Increase in adoption of regenerative medicine, new medical grade gelatin range launched by prominent market players, and expanding applications of low grade gelatin in medicine primarily drive the global low endotoxin gelatin market

For instance, in May 2018, Rousselot, the manufacturer of gelatin and collagen peptides, launched X-Pure, a medical grade gelatin range for in-body applications. The product has applications in hemostatic medical device, parenteral formulations, and regenerative medicine.

A company named Nitta Gelatin, NA Inc. manufacturers pharmaceuticals and food. beMatrix, is a low endotoxin gelatin, having applications in scientific research and medical devices.

Rise in efforts by prominent market players in supplying new product-line of materials for biomedical use is expected to boost the low endotoxin gelatin market

However, stringent regulatory requirements governing the use of low endotoxin gelatin in medical applications is likely to restrain the growth of the market during the forecast period

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=76802

Source Segment to Account for Major Share of Global Market

Based on source, the global low endotoxin gelatin market can be classified into porcine skin and bovine skin

The porcine skin segment is anticipated to dominate the global market during the forecast period, owing to an increase in number of new products from porcine skin based low endotoxin grade

Regenerative Medicine Segment to Offer Significant Opportunities

In terms of application, the global low endotoxin gelatin market can be segmented into hemostatic applications, drug delivery & parenteral applications, biomedical applications, regenerative medicine applications, and others. The regenerative medicine applications segment is further categorized into implantable membranes, 3D bioprinting, stem cell & organoid culturing, and others.

The regenerative medicine applications segment is expected to gain significant share of share the global low endotoxin gelatin market by 2027. Increase in demand for low endotoxin gelatin in regenerative medicines is likely to drive the segment. Gelatin-based delivery systems used for targeted release for biomolecules are expected to gain importance. Reduction in endotoxin levels in gelatin is primarily important in regenerative medicine which has led to an increase in research & development activities for developing wide range of low endotoxin gelatin.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=76802

North America to Dominate Global Low Endotoxin Gelatin Market

In terms of region, the global low endotoxin gelatin market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global low endotoxin gelatin market during the forecast period.

Recent product launch in the U.S., presence of prominent market players, extensive growth of regenerative medicine, and rise in demand for drug delivery technologies are various factors projected to drive the market in North America

Key Players Operating in Global Low Endotoxin Gelatin Market

The global low endotoxin gelatin market is highly fragmented, with a large number of domestic players accounting for a major market share. Key players operating in the global low endotoxin gelatin market are:

More Trending Reports by Transparency Market Research

Womens Health Diagnostics Market: Companies in the womens health diagnostics market are offering increased laboratory testing options to assess biomarkers for allergies, thyroid, and renal diseases in women.

Laboratory Information Systems Market: The value of the global laboratory information systems market size stood at US$ 2.2 Bn in 2021. The global market is projected to grow at a CAGR of 8.3% from 2022 to 2031.

Travelers Diarrhea Treatment Market: The market for travelers diarrhea treatment is expected to reach a value of ~US$ 1.3 Bn by 2027.

Hereditary Angioedema Treatment Market: The global hereditary angioedema treatment market is projected to reach a value of ~US$ 5 Bn by 2027, expanding at a CAGR of ~9% from 2019 to 2027.

Biological Imaging Reagents Market: The global biological imaging reagents market was valued at ~US$ 13.5 Bn in 2018 and is projected to expand at a CAGR of 8.5%, to reach ~US$ 28 Bn by 2027.

Point-of-Care Coagulation Testing Devices Market: The global point-of-care coagulation testing devices market is anticipated to reach more than US$ 3.06 Bn by 2031.

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: The global IBD (ulcerative colitis & Cohn's disease) treatment market is anticipated to reach more than US$ 34.22 Bn by 2031.

Stroke Treatment Market: The global stroke treatment market was valued at ~US$ 8 Bn in 2018. Projected to grow at a CAGR of ~7% over the forecast period, the global stroke treatment market is expected to reach a value of ~US$ 15 Bn by the year 2027.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

See the original post here:
Low Endotoxin Gelatin Market Expected to Witness a Sustainable Growth by 2027 - BioSpace

Technology in the service of health. Once again, technological progress has resulted in obvious benefits to humans; In this case, in health matters. a group of scientists has developed a robotic system based on artificial intelligence that automatically determines what are the optimal conditions for the replacement layers of the retina to grow Required in various treatments aimed at restoring vision.

During the last experiment, The system underwent a trial and error process covering a total of 200 million possible configurations and managed to dramatically improve cell culture viability Regenerative medicine is essential to the therapy. A feat that exemplifies how the automated design and execution of scientific experiments can increase the efficiency and speed of research in countless fields such as biology.

Traditionally, research in regenerative medicine has required a number of experiments that require a great deal of time and work. especially, Creating specific tissues from stem cells a process called induced cell differentiation takes months of work, and the degree of success depends on a wide range of variables., Finding the optimal type, dosage and timing of reagents as well as optimal physical variables, such as cell transfer time or temperature, is difficult and requires an enormous amount of testing.

Thus, to make this process more efficient and practical, a research team led by Genki Kanda from the RIKEN Institute in Japan set out to Develop an autonomous experimental system that can determine optimal conditions and grow functional retinal pigment layers from stem cells, For this Retinal pigment epithelial cells were selected Because the degeneration of these cells is a common aging-related disorder that makes people unable to see. More importantly, transplanted retinal pigment epithelial layers have already shown some clinical success.

For autonomous experiments to be successful, the robot must perform the same series of precise movements and manipulations over and over again; And artificial intelligence, for its part, should be able to evaluate the results and prepare for the next experiment. The new system accomplishes these goals, thanks to a general-purpose humanoid robot called Maholo, which is capable of conducting high-precision biological experiments. Maholo to a. is controlled by software Artificial Intelligence that uses a newly designed optimization algorithm To determine which parameters should be changed, and how they should be changed, to improve the differentiation efficiency in the next round of experiments.

In what would have taken human researchers more than two and a half years, robotic systems with artificial intelligence took only 185 days. translate the Go from initial efficiency to 90% in resolution rate of 50% for experiment and improvement work Created by Robot.

Read the original post:
Robotics And AI As Accelerators Of Advances In Regenerative Medicine - Nation World News